The Experts below are selected from a list of 222201 Experts worldwide ranked by ideXlab platform
Achille Iolascon - One of the best experts on this subject based on the ideXlab platform.
-
How I Diagnose Non-thalassemic Microcytic Anemias.
Seminars in hematology, 2015Co-Authors: Mariasole Bruno, Luigia De Falco, Achille IolasconAbstract:Microcytic Anemia is the most common form of Anemia, characterized by reduced hemoglobin (Hb) synthesis associated with decreased red blood cell volume (MCV). It is a very heterogeneous group of diseases that may be either acquired or inherited. Microcytic hypochromic Anemia can result from defects in globin (hemoglobinopathies or thalassemias) or heme synthesis or in iron availability, or acquisition by the erythroid precursors. Diagnosis of microcytic anaemia appears to be important in children/adolescents, especially to set, where possible, a treatment plan on the basis of the etiology and pathogenesis. After excluding the acquired causes of microcytic Anemia that represent the most frequent etiology, according to the differential diagnosis, the analysis of genetic causes, mostly hereditary, must be considered. This review will consider acquired and hereditary microcytic Anemias due to heme synthesis or to iron metabolism defects and their diagnosis.
-
the human counterpart of zebrafish shiraz shows sideroblastic like microcytic Anemia and iron overload
Blood, 2007Co-Authors: Clara Camaschella, Luigia De Falco, Alessandro Campanella, Loredana Boschetto, Roberta Merlini, Laura Silvestri, Sonia Levi, Achille IolasconAbstract:Inherited microcytic-hypochromic Anemias in rodents and zebrafish suggest the existence of corresponding human disorders. The zebrafish mutant shiraz has severe Anemia and is embryonically lethal because of glutaredoxin 5 (GRLX5) deletion, insufficient biogenesis of mitochondrial iron-sulfur (Fe/S) clusters, and deregulated iron-regulatory protein 1 (IRP1) activity. This leads to stabilization of transferrin receptor 1 (TfR) RNA, repression of ferritin, and ALA-synthase 2 (ALAS2) translation with impaired heme synthesis. We report the first case of GLRX5 deficiency in a middle-aged anemic male with iron overload and a low number of ringed sideroblasts. Anemia was worsened by blood transfusions but partially reversed by iron chelation. The patient had a homozygous (c.294A>G) mutation that interferes with intron 1 splicing and drastically reduces GLRX5 RNA. As in shiraz, aconitase and H-ferritin levels were low and TfR level was high in the patient's cells, compatible with increased IRP1 binding. Based on the biochemical and clinical phenotype, we hypothesize that IRP2, less degraded by low heme, contributes to the repression of the erythroblasts ferritin and ALAS2, increasing mitochondrial iron. Iron chelation, redistributing iron to the cytosol, might relieve IRP2 excess, improving heme synthesis and Anemia. GLRX5 function is highly conserved, but at variance with zebrafish, its defect in humans leads to Anemia and iron overload.
Marc Anders - One of the best experts on this subject based on the ideXlab platform.
-
Anemia is associated with greater morbidity and resource utilization in pediatric patients with systolic heart failure a multi institutional analysis
Journal of Heart and Lung Transplantation, 2019Co-Authors: Kriti Puri, Morales R Demori, Paul A Checchia, Marc AndersAbstract:Purpose Data are limited about Anemia and its association with outcomes in pediatric patients with systolic heart failure (HF). Methods Retrospective cohort study querying the Pediatric Health Information System (PHIS) database (comprised of 50 children's hospitals) from 01/2008 to 12/2017. Admissions of patients aged Results 2494 admissions met inclusion criteria - median age 9yr (IQR 1-15yr), 54% (1,341) male. Anemia was present in 26% (648) of the patients. The anemic cohort was younger (median 6yr vs 9yr, p=0.003) and had female preponderance (50% vs 45%, p=0.016) compared to the non-anemic cohort. The anemic group were more likely to undergo mechanical ventilation (64% vs 51%, p Conclusion Anemia is associated with more comorbidities and resource utilization in pediatric patients admitted for systolic HF. This suggests a need for examining Anemia management strategies to optimize pediatric HF outcomes.
Peter Van Der Meer - One of the best experts on this subject based on the ideXlab platform.
-
Anemia and mortality in heart failure patients a systematic review and meta analysis
Journal of the American College of Cardiology, 2008Co-Authors: Hessel F Groenveld, James L Januzzi, Kevin Damman, Jan Van Wijngaarden, Hans L Hillege, Dirk J Van Veldhuisen, Peter Van Der MeerAbstract:Objectives The aim of this study was to assess the effect of Anemia on mortality in chronic heart failure (CHF). Background Anemia is frequently observed in patients with CHF, and evidence suggests that Anemia might be associated with an increased mortality. Methods A systematic literature search in MEDLINE (through November 2007) for English language articles was performed. In addition, a manual search was performed. We included cohort studies and retrospective secondary analyses of randomized controlled trials whose primary objective was to analyze the association between Anemia and mortality in CHF. Of a total of 1,327 initial studies, we included 34 studies, comprising 153,180 patients. Information on study design, patient characteristics, outcome, and potential confounders were extracted. Results Anemia was defined by criteria used in the original articles. Of the 153,180 CHF patients, 37.2% were anemic. After a minimal follow-up of 6 months, 46.8% of anemic patients died compared with 29.5% of nonanemic patients. Crude mortality risk of Anemia was odds ratio 1.96 (95% confidence interval: 1.74 to 2.21, p Conclusions Anemia is associated with an increased risk of mortality in both systolic and diastolic CHF. Anemia should, therefore, be considered as a useful prognosticator, and therapeutic strategies aimed to increase hemoglobin levels in CHF should be investigated.
J W Shearer - One of the best experts on this subject based on the ideXlab platform.
-
Anemia vs iron deficiency increased risk of preterm delivery in a prospective study
The American Journal of Clinical Nutrition, 1992Co-Authors: Theresa O Scholl, Mary L Hediger, Richard L Fischer, J W ShearerAbstract:Using criteria from the Centers for Disease Control, Anemia and iron-deficiency Anemia (Anemia with serum ferritin concentrations less than 12 micrograms/L) were assessed in greater than 800 inner-city gravidas at entry to prenatal care. Iron-deficiency Anemia was associated with significantly lower energy and iron intakes early in pregnancy and a lower mean corpuscular volume. The odds of low birth weight were tripled and of preterm delivery more than doubled with iron deficiency, but were not increased with Anemia from other causes. When vaginal bleeding at or before entry to care accompanied Anemia, the odds of a preterm delivery were increased fivefold for iron-deficiency Anemia and doubled for other Anemias. Inadequate pregnancy weight gain was more prevalent among those with iron-deficiency Anemia and in those with Anemias of other etiologies. The prevalence of iron-deficiency Anemia (3.5%), however, was lower than anticipated for an inner-city, minority population in whom most Anemias had been attributed clinically to iron deficiency.
Elias Jimenez - One of the best experts on this subject based on the ideXlab platform.
-
iron deficiency Anemia and infant development effects of extended oral iron therapy
The Journal of Pediatrics, 1996Co-Authors: Betsy Lozoff, Abraham W Wolf, Elias JimenezAbstract:OBJECTIVE: To determine whether extended oral iron therapy corrects lower developmental test scores in infants with iron-deficiency Anemia. STUDY DESIGN: Double-blind, controlled trial in Costa Rica involving 32 12- to 23-month-old infants with iron-deficiency Anemia and 54 nonanemic control subjects. Anemic infants were treated with orally administered iron for 6 months; half the nonanemic children were treated with iron and half with placebo. Developmental test scores and hematologic status were evaluated before treatment, after 3 months, and after 6 months. RESULTS: Iron-deficient anemic infants received lower mental test scores than nonanemic infants at all three time points (p <0.05 pretreatment and at 3 months, p = 0.07 at 6 months). There were no significant differences in motor test scores. More of the anemic infants were rated as unusually fearful and unhappy. Anemic infants came from families with lower maternal education and less support for child development and were less likely to be breast fed, were weaned earlier, and consumed more cow milk. CONCLUSIONS: Lower mental test scores persisted in infants with iron-deficiency Anemia despite extended oral iron therapy and an excellent hematologic response. Iron-deficiency Anemia may serve as a marker for a variety of nutritional and family disadvantages that may adversely affect infant development. (J PEDIATR 1996;129:382-9)